The Food and Drug Administration announced on Apr. 2 that new modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) will be implemented starting August 8, 2026. The changes are designed to reduce burdens for pharmacists, patients, and prescribers while maintaining safety measures for isotretinoin use.
The upcoming adjustments will allow patients, if permitted by their prescriber, to complete pregnancy testing outside of a medical setting during and after isotretinoin treatment. Additionally, the agency has removed the requirement for a 30-day prescription timeframe for patients who cannot become pregnant.
Other updates include a mandate that pharmacies must reverse REMS authorization and restock prescriptions if they are not picked up by patients. Pharmacy staff will also be required to complete annual REMS training. Certified pharmacies must ensure that an authorized representative maintains documentation of this training.
These changes aim to streamline procedures while continuing efforts to prevent potential risks associated with isotretinoin use. The FDA stated that these modifications will take effect exactly 180 days from February 9, 2026.
Alerts Sign-up